Climb Bio, Inc. (CLYM) vs Ironwood Pharmaceuticals, Inc. (IRWD)
A side-by-side comparison of Climb Bio, Inc. and Ironwood Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CLYM
Climb Bio, Inc.
$10.69HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
IRWD
Ironwood Pharmaceuticals, Inc.
$3.63HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — CLYM vs IRWD
growth of $100 · dividends reinvested · last 2yCLYM +41.1% (+18.8%/yr)IRWD -26.4% (-14.2%/yr)CLYM compounded faster over this window
CLYM IRWD
CLYM vs IRWD: by the numbers
- •CLYM is the larger company ($612M vs $598M market cap).
- •IRWD is profitable (33.36% net margin) while CLYM runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | CLYM | IRWD |
|---|---|---|
| P/E ratio | N/A | 4.73 |
| Forward P/E | N/A | 2.97 |
| P/S ratio | N/A | 1.53 |
| P/B ratio | 2.56 | N/A |
| EV / EBITDA | N/A | 3.85 |
| FCF yield | N/A | 31.05% |
Profitability
| Metric | CLYM | IRWD |
|---|---|---|
| Gross margin | 0.00% | 99.76% |
| Operating margin | 0.00% | 40.10% |
| Net margin | 0.00% | 33.36% |
| ROE | -24.06% | N/A |
| ROIC | -26.94% | 58.60% |
Growth (annualized)
| Metric | CLYM | IRWD |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -1.18% |
| EPS CAGR (5Y) | N/A | -25.87% |
| FCF CAGR (5Y) | N/A | -3.98% |
| Total return CAGR (5Y) | N/A | -22.82% |
Frequently asked
- Is CLYM or IRWD more profitable?
- IRWD runs the higher net margin — CLYM at 0.00% versus IRWD at 33.36%.
Go deeper
Dig into the metrics
Ironwood Pharmaceuticals P/E ratioClimb Bio ROEIronwood Pharmaceuticals ROEClimb Bio operating marginIronwood Pharmaceuticals operating marginClimb Bio revenue growthIronwood Pharmaceuticals revenue growthClimb Bio free cash flowIronwood Pharmaceuticals free cash flow
Climb Bio & Ironwood Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.